Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Lancet (London, England)|July 11, 2021
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trialChristopher Sweeney, Sergio Bracarda, Cora N Sternberg, et al.
The New England Journal of Medicine|June 6, 2019
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic MelanomaCaroline Robert, Jean J Grob, Daniil Stroyakovskiy, et al.
Therapeutic Advances in Medical Oncology|June 5, 2023
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy Dennis J Slamon, Peter A Fasching, Sara Hurvitz, et al.
International Journal of Cancer|June 11, 2026
Surgical Removal of Residual Tumor Masses in Patients Undergoing Targeted Therapy for EGFR-Mutated Locally Advanced or Metastatic Lung CancerFedor Moiseenko, Daniil Stroyakovskiy, Evgeniy Levchenko, et al.
The New England Journal of Medicine|March 20, 2024
Ribociclib plus Endocrine Therapy in Early Breast CancerDennis Slamon, Oleg Lipatov, Zbigniew Nowecki, et al.
Lancet (London, England)|June 4, 2015
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2021
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanomaAlexander Mm Eggermont, Andrey Meshcheryakov, Victoria Atkinson, et al.
The New England Journal of Medicine|September 30, 2014
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
European Journal of Cancer (Oxford, England : 1990)|August 12, 2025
Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trialLev Demidov, Igor Samoylenko, Galina Kharkevich, et al.
The New England Journal of Medicine|September 9, 2025
Overall Survival with Amivantamab-Lazertinib in <i>EGFR</i>-Mutated Advanced NSCLCJames Chih-Hsin Yang, Shun Lu, Hidetoshi Hayashi, et al.
Pageof 5